ABBV-RGX-314 Dose 2

GENETIC3 trials

Sponsors

AbbVie

Conditions

AMDCNVCenter-Involved Diabetic Macular Edema (CI-DME)Diabetic Retinopathy (DR)Neovascular Age-Related Macular Degeneration (nAMD)Wet Age-related Macular DegenerationWetAMDnAMD

Phase 2

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Active, not recruitingNCT04514653

AbbVieNeovascular Age-Related Macular Degeneration (nAMD)

Start: 2020-08-25End: 2027-02-01Updated: 2026-02-27

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

Active, not recruitingNCT04567550

AbbVieCenter-Involved Diabetic Macular Edema (CI-DME), Diabetic Retinopathy (DR)

Start: 2020-11-20End: 2026-12-31Updated: 2025-09-17

Phase 3

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

RecruitingNCT05407636

AbbVieAMD, CNV, nAMD +3

Start: 2022-01-13End: 2027-11-30Target: 660Updated: 2025-09-25

Related Papers

Viral Vector Technologies and Strategies: Improving on Nature

International Ophthalmology Clinics2021-07-015 citations